KORU Medical Systems, Inc. (KRMD)

KORU Medical Systems' stock (KRMD) has experienced fluctuations, with a 35.54% increase over the last 12 months, but a decrease of 12.30% in the past month and 6.29% over the last three months as of February 25, 2026. Key events include preliminary Q4 and full-year 2025 results showing revenue growth and positive cash flow, FDA clearance for RYSTIGGO, a 510(k) submission for an oncology biologic, analyst ratings of "Moderate Buy" or "Strong Buy" with price targets ranging from $6.00 to $8.00, and a stock price dip in February 2026 considered a potential turnaround.

There is no explicit indication of strong demand seasonality for KORU Medical Systems, Inc.'s products and services. The company's business revolves around providing subcutaneous infusion systems for patients with chronic illnesses, which require consistent administration, suggesting a relatively stable and recurring demand. The company has reported continued strength in its core immunoglobulin business and growth in its recurring patient base, further supporting the notion of a consistent demand profile.

KORU Medical Systems, Inc. is a medical technology company focused on developing, manufacturing, and commercializing subcutaneous infusion solutions, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies and Health Care Equipment industries. The company provides patient-centric large volume subcutaneous infusion systems, including the Freedom Integrated Infusion System, which delivers life-saving therapies for chronic illnesses. Formerly known as Repro Med Systems, Inc., the company rebranded to KORU Medical Systems, Inc. in March 2022.

KORU Medical Systems, Inc. is headquartered in Mahwah, New Jersey, United States. The company develops, manufactures, and commercializes its subcutaneous infusion solutions for the subcutaneous drug delivery market in the United States and internationally, with an active international expansion strategy.

KORU Medical Systems' brand reputation is generally positive, supported by "Moderate Buy" or "Strong Buy" recommendations from analysts and achievements like FDA 510(k) clearance for RYSTIGGO and a 510(k) submission for an oncology biologic. The company's focus on home and specialty infusion solutions, responsive problem-solving, and patient experience contributes to a positive brand image. Continued strength in the core immunoglobulin business and growth in the recurring patient base also suggest customer satisfaction and trust.

KORU Medical Systems, Inc. has significant institutional ownership, with 134 institutional owners and shareholders holding 22,185,115 shares, representing approximately 57.04% to 58.6% of the total shares. Major institutional owners include First Light Asset Management, LLC, Topline Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Individual ownership information is less detailed, but Linda M. Tharby, the President, CEO, and Director, holds a notable percentage of shares.